Related Experiment Videos
High-density lipoprotein cholesterol and treatment guidelines
1Department of Cardiology, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia. ton@austin.unimelb.edu.au
Insights
New guidelines are emerging to manage high-density lipoprotein cholesterol (HDL-C) levels. Incorporating HDL-C targets improves cardiovascular outcomes, especially for high-risk patients.
Area of Science:
- Cardiovascular Medicine
- Lipidology
- Clinical Guideline Development
Background:
- Lipid management guidelines often lack precision and practicality.
- High-density lipoprotein cholesterol (HDL-C) has been historically underutilized as a cardiovascular risk predictor and therapeutic target.
- Recent research highlights HDL-C's role in atherosclerotic disease pathophysiology.
Purpose of the Study:
- To advocate for the incorporation of HDL-C into clinical guidelines.
- To establish clear threshold and target levels for HDL-C management.
- To improve cardiovascular outcomes through practical guideline implementation.
Main Methods:
- Review of current lipid management guidelines.
- Analysis of recent clinical trial data on HDL-C.
- Consideration of factors balancing specialist precision and general practitioner practicality.
Main Results:
- Growing recognition of HDL-C's significance in cardiovascular risk.
- Clinical trial evidence supports increasing low HDL-C levels to reduce cardiovascular events.
- Guidelines incorporating HDL-C targets offer a practical approach to patient management.
Conclusions:
- Consistent lipid management guidelines require balancing precision and practicality.
- HDL-C should be integrated into guidelines as a key therapeutic target.
- Managing HDL-C levels in high-risk populations, including the elderly and those with type 2 diabetes, can improve patient outcomes.
Abstract:
Setting consistent guidelines for the treatment of lipid abnormalities must take into consideration several factors and must balance the need for precision (favored by specialists) and practicality in the patient setting (favored by general medical practitioners). The appropriate populations for treatment should be clearly defined, and usual threshold levels, target levels, and treatment should be well established. Plasma high-density lipoprotein cholesterol (HDL-C) has not been widely incorporated in guidelines as a significant abnormality predictive of cardiovascular risk and as a therapeutic target. However, that view is changing in the light of recent improved understanding of the importance of each lipid fraction abnormality, including HDL-C, in the pathophysiology of atherosclerotic disease. In addition, clinical trials have demonstrated the apparent benefit of increasing low levels of HDL-C in reducing cardiovascular events. The use of guidelines incorporating threshold and target levels for managing HDL-C in high-risk populations is becoming seen as a practical means of improving the outcome for patients, especially for special groups, such as the elderly and those with type 2 diabetes mellitus.